Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

ClinicalTrials.gov ID: NCT01987960

Public ClinicalTrials.gov record NCT01987960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.

Study identification

NCT ID
NCT01987960
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
H. Lundbeck A/S
Industry
Enrollment
417 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2013 (Type not available)
Primary completion
Oct 2015 (Actual)
Completion
Oct 2015 (Actual)
Last update posted
Mar 13, 2017

2013 – 2015

United States locations

U.S. sites
22
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
US004 Los Angeles California 90024 —
US025 Los Angeles California 90102 —
US024 Riverside California 92504 —
US015 San Diego California 90103 —
US008 San Diego California 92123 —
US002 Bradenton Florida 34201 —
US006 Gainesville Florida 32607 —
US016 Jacksonville Florida 32256 —
US020 North Miami Florida 33161 —
US017 Tampa Florida 33609 —
US012 Indianapolis Indiana 46260 —
US021 Roslindale Massachusetts 02131 —
US019 Las Vegas Nevada 89102 —
US007 Nashua New Hampshire 03060 —
US001 The Bronx New York 10467 —
US009 Cincinnati Ohio 45219 —
US005 Dayton Ohio 45417 —
US010 Portland Oregon 97210 —
US014 Norristown Pennsylvania 19403 —
US011 Memphis Tennessee 38119 —
US003 Austin Texas 78731 —
US026 Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01987960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 13, 2017 · Synced Oct 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01987960 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →